These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 8681309

  • 21. Gabapentin in the management of convulsive disorders.
    McLean MJ.
    Epilepsia; 1999; 40 Suppl 6():S39-50; discussion S73-4. PubMed ID: 10530682
    [Abstract] [Full Text] [Related]

  • 22. [Gabapentin--a new antiepileptic agent].
    Nakken KO, Rytter E, Johannessen SI.
    Tidsskr Nor Laegeforen; 1998 Feb 28; 118(6):872-4. PubMed ID: 9543799
    [Abstract] [Full Text] [Related]

  • 23. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
    Parsons B, Tive L, Huang S.
    Am J Geriatr Pharmacother; 2004 Sep 28; 2(3):157-62. PubMed ID: 15561647
    [Abstract] [Full Text] [Related]

  • 24. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy.
    Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH.
    Ann Neurol; 1996 Jan 28; 39(1):95-9. PubMed ID: 8572673
    [Abstract] [Full Text] [Related]

  • 25. Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy.
    Lücke A, Musshoff U, Köhling R, Osterfeld M, Mayer T, Wolf P, Schütte W, Speckmann EJ.
    Br J Pharmacol; 1998 May 28; 124(2):370-6. PubMed ID: 9641555
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy and tolerance of long-term, high-dose gabapentin: additional observations.
    Handforth A, Treiman DM.
    Epilepsia; 1994 May 28; 35(5):1032-7. PubMed ID: 7925148
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Gabapentin: a unique anti-epileptic agent.
    Dougherty JA, Rhoney DH.
    Neurol Res; 2001 Dec 28; 23(8):821-9. PubMed ID: 11760873
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Mechanisms of action of gabapentin.
    Taylor CP.
    Rev Neurol (Paris); 1997 Dec 28; 153 Suppl 1():S39-45. PubMed ID: 9686247
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Gabapentin: discussion.
    Fromm GH.
    Epilepsia; 1994 Dec 28; 35 Suppl 5():S77-80. PubMed ID: 8039476
    [Abstract] [Full Text] [Related]

  • 36. Gabapentin dosing in the treatment of epilepsy.
    McLean MJ, Gidal BE.
    Clin Ther; 2003 May 28; 25(5):1382-406. PubMed ID: 12867216
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Emerging perspectives on the mechanism of action of gabapentin.
    Taylor CP.
    Neurology; 1994 Jun 28; 44(6 Suppl 5):S10-6; discussion S31-2. PubMed ID: 7517515
    [Abstract] [Full Text] [Related]

  • 39. A case of cutaneous leukocytoclastic vasculitis associated with gabapentin.
    Poon DY, Law NM.
    Singapore Med J; 2003 Jan 28; 44(1):42-4. PubMed ID: 12762564
    [Abstract] [Full Text] [Related]

  • 40. Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions.
    Patsalos PN.
    Seizure; 1994 Sep 28; 3(3):163-70. PubMed ID: 8000709
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.